Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Chemotherapy Followed by Liver Transplantation for Unresectable Cholangiocarcinoma
NCT01151761Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Jan 2011
- Primary completion
- Apr 2012
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, Cisplatin micelle injection (HA132), carboplatin, capecitabine and fluorouracil in cholangiocarcinoma (CCA), sponsored by Stanford University. Primary endpoint: Progression-free Survival at 12 months. Started Jan 2011; status: terminated.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)carboplatincapecitabinefluorouracil
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT01151761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151761.